Working… Menu

A Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Pepinemab (VX15/2503) (SIGNAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02481674
Recruitment Status : Completed
First Posted : June 25, 2015
Last Update Posted : September 17, 2020
Huntington Study Group
Information provided by (Responsible Party):
Vaccinex Inc.